FLOKI, NRx Pharmaceuticals, BioVie & PetVivo Set to Disrupt Healthcare, Gaming & Sports – “New to The Street” on Bloomberg Tonight
NEW YORK CITY, NY – August 9, 2025 – Get ready for a powerhouse episode of New to The Street, airing tonight at 6:30 PM EST on Bloomberg. The show, a mainstay of business television for over 16 years, will spotlight four companies poised for meaningful growth in healthcare, blockchain gaming, and the equine industry: BioVie Inc. (NASDAQ:BIVI), FLOKI, petvivo Holdings, Inc. (NASDAQ:PETV), and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP).
(Image: A dynamic collage featuring logos of all four companies – BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals – with the Bloomberg logo prominently displayed.)
This week’s episode, presented as sponsored programming, will also feature the television debut of FLOKI’s commercial, introducing their rapidly expanding Valhalla Game to a national audience.
Here’s a breakdown of what to expect:
FLOKI: Gaming Meets Real-World Utility
Pedro Vidal,Chief Relationship Officer of FLOKI,will discuss the platform’s dominance with the FLOKI Trading Bot on the BNB Chain,empowering traders with advanced tools. But the real excitement lies with Valhalla Game, where players are already earning Vera tokens – with over 100,000 already minted – that have tangible value outside the game. This groundbreaking integration of blockchain technology is redefining the gaming experience. Learn more at FLOKI.com and Valhalla.Game
NRx Pharmaceuticals: Challenging Ketamine Standards for Mental Health
Jonathan Javitt, Founder, Chairman, and CEO of nrx Pharmaceuticals, will detail the company’s Citizen Petition to the FDA, advocating for the removal of the toxic preservative benzethonium chloride from all ketamine formulations. NRx has already developed a preservative-free choice with proven three-year stability and is pursuing FDA approval, possibly including a breakthrough designation for treating suicidal depression.
BioVie Inc.: A Potential Game-Changer for Parkinson’s & Long COVID
Cuong Do, President and CEO of BioVie, will provide crucial updates on two pivotal Phase 3 clinical trials for Bezisterim. The first trial could deliver the first new therapy for Parkinson’s disease in over 50 years, targeting newly diagnosed patients. The second trial investigates Bezisterim’s potential to alleviate debilitating brain fog and fatigue associated with Long COVID, impacting an estimated 17 million Americans. Top-line data is anticipated in the first half of 2026.
PetVivo Holdings: Revolutionizing Equine Wellness
John Lai,CEO of PetVivo Holdings,will join Chase Chamberlin of Commonwealth to discuss their strategic partnership aimed at enhancing the well-being of thoroughbred racehorses. Their focus? SPRYNG™ with OsteoCushion™ Technology, a natural solution for maintaining optimal joint health in these elite athletes.
Don’t Miss Out!
Tune in to New to The Street on Bloomberg tonight at 6:30 PM EST to gain valuable insights into these innovative companies and the future of their respective industries.
about New to the Street:
With over 16 years of experience and more than 2,000 interviews, New to The Street is a leading business television brand. Its comprehensive media ecosystem – including Bloomberg and Fox Business broadcasts, a rapidly growing YouTube channel with over 3.16 million subscribers,
